IEM Awarded GSA OASIS+ IDIQ Contract
MORRISVILLE, N.C., Jan. 30, 2025 /PRNewswire/ -- IEM International, Inc., a national leader in emergency management, disaster recovery, and critical infrastructure solutions, is proud to announce its award of the General Services Administration (GSA) One Acquisition Solution for Integrated Services Plus (OASIS+) Unrestricted Indefinite Delivery, Indefinite Quantity (IDIQ) contract. This milestone expands IEM's ability to support federal agencies with high-quality, comprehensive management, advisory, and logistics services.
"IEM's award of the GSA OASIS+ contract reaffirms our position as a trusted partner to the federal government. Through OASIS+, we are eager to leverage our four decades of expertise in disaster recovery, emergency management, and critical infrastructure to support critical missions and deliver innovative, impactful solutions," said IEM President and CEO Bryan Koon. "This achievement reflects the dedication and collaboration of our entire team, and we look forward to helping drive resilience and readiness across federal agencies."
The GSA OASIS+ contract, a premier government-wide acquisition vehicle, provides federal agencies with streamlined access to a broad range of professional services. With a performance period until December 16, 2029—plus an option period extending through 2034—this contract will enhance IEM's capacity to deliver innovative and mission-critical solutions across federal agencies.
Through this award, IEM is approved to compete for and execute task orders across 27 Contract Line Item Numbers (CLINs) across two key domains, Management & Advisory and Logistics:
Management & Advisory: Providing expert consulting services to enhance agency performance, achieve mission objectives, and optimize administrative and management operations.
Logistics: Delivering comprehensive logistics solutions, including planning, implementation, and operational support for the movement of supplies, equipment, and personnel across multiple transportation modes.
"The OASIS+ contract is a significant opportunity and strategic win for IEM, expanding our reach and delivery of exceptional service to federal agencies," said Allison Patrick, IEM Chief Growth Officer. "Our expertise in management, logistics, and critical infrastructure solutions makes us a trusted partner in strengthening government capabilities and achieving mission success."
Federal agencies seeking to engage IEM's services can find more information on the GSA OASIS+ program website (https://www.gsa.gov/oasis-plus/) or our contract vehicles page (https://iem.com/work-with-us/contract-vehicles/).
About IEMIEM is the world's largest woman- and minority-owned management consulting firm, dedicated to building a safe, secure, and resilient world. Since 1985, we have partnered with federal, state, local, tribal, and territorial governments to deliver innovative, science-driven solutions in emergency management, disaster recovery, critical infrastructure, public safety, logistics, public health, digital citizen services, public engagement, and more. Integrating technology, real-world expertise, and strategic insight, IEM helps communities prepare for, respond to, recover from, and mitigate the most complex challenges. Learn more at iem.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/iem-awarded-gsa-oasis-idiq-contract-302364886.html
SOURCE IEM International, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
Yahoo
2 days ago
- Yahoo
Cool Off This August with Root Beer Ice Cream at Cold Stone Creamery®
SCOTTSDALE, Ariz., Aug. 1, 2025 /PRNewswire/ -- Cold Stone Creamery® ( is bringing nostalgic flavors to the forefront this summer with the launch of its limited-time Root Beer Ice Cream, available now through August 31. Inspired by the classic soda fountain favorite, this flavor offers a refreshing and creamy twist on a beloved American tradition. Root Beer Ice Cream is handcrafted fresh in every store and can be enjoyed on its own or as part of two delicious offerings. The Root Beer Revival Creation™ mixes Root Beer Ice Cream with chocolate chips, caramel, and whipped topping, while the Go With the Float, our take on the classic soda shop root beer float, features Root Beer Ice Cream and root beer topped with whipped topping and a maraschino cherry. "Root Beer Ice Cream is a nostalgic flavor that instantly takes you back in time," said Courtney Maxedon VP of Marketing and Digital Strategy at Kahala Brands™, parent company of Cold Stone Creamery. "We wanted to capture that classic root beer float experience and serve it up in a way that only Cold Stone can - bold, creamy, and full of flavor." Don't miss your chance to experience this limited-time flavor. Whether you're reliving childhood memories or discovering root beer in a whole new way, our Root Beer Ice Cream is the perfect way to cool off your August. Available in stores and online, this ice cream won't be around for long, so grab it while you can! Promotional Flavor: Root Beer Ice Cream Promotional Creation™: Root Beer Revival - Root Beer Ice Cream, Chocolate Chips, Caramel & Whipped Topping Promotional Float: Go With the Float - Root Beer Ice Cream, Root Beer, Whipped Topping & a Maraschino Cherry About Cold Stone CreameryCold Stone Creamery® delivers the Ultimate Ice Cream Experience® through a community of franchisees who are passionate about ice cream. The secret recipe for smooth and creamy ice cream is handcrafted fresh daily in each store, and then customized by combining a variety of mix-ins on a frozen granite stone. Headquartered in Scottsdale, Arizona, Cold Stone Creamery is owned by parent company Kahala Brands™, one of the fastest growing franchising companies in the world with a portfolio of nearly 30 fast-casual and quick-service restaurant brands with approximately 3,000 locations in 35 countries. The Cold Stone Creamery brand operates nearly 1,500 locations globally in approximately 30 countries worldwide. For more information about Cold Stone Creamery, visit View original content to download multimedia: SOURCE Cold Stone Creamery Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit View original content to download multimedia: SOURCE OSR Holdings Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
